

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Rispoval IBR-Marker Inactivated

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One dose (2 ml) contains:

**Active substance:**

Bovine Herpes Virus type 1 (BoHV-1), strain Difivac (gE-negative), to induce a geometric mean seroneutralizing titre of at least 1:160 in cattle.

**Adjuvant(s):**

Aluminium hydroxide	14-24 mg
Quil A	0.25 mg

**Excipient(s):**

<i>Preservative</i>	
Thiomersal	0.2 mg

For a full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Suspension for injection.

Pinkish liquid suspension, which might contain loose sediment.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Cattle

#### **4.2 Indications for use, specifying the target species**

For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce the clinical signs and virus shedding and, in female cattle, to prevent abortions associated with BoHV-1 infection. The vaccination of pregnant cattle will prevent abortion associated with BoHV-1 infections as demonstrated during the second trimester of gestation upon challenge 28 days after vaccination. Vaccinated cattle can be differentiated from field virus infected animals due to the marker

deletion, unless the cattle were previously vaccinated with a conventional vaccine or infected with field virus.

Duration of immunity: 6 months

- For booster immunisation after primovaccination with Rispoval IBR-Marker Vivum (in member states where this product is authorized) to reduce the virus shedding and the clinical signs associated with BoHV-1 infection in cattle and, in female cattle, to prevent abortions associated with BoHV-1 infection. This vaccination of cattle will prevent abortion associated with BoHV-1 infections as demonstrated during the third trimester of gestation upon challenge 86 days after the booster vaccination.

Duration of immunity: 6 months after complete primovaccination with Rispoval IBR-Marker Vivum followed by 12 months after annual booster with Rispoval IBR-Marker Inactivatum.

In order to prevent abortion in female cattle that have received basic immunisation, a single dose revaccination with Rispoval IBR-Marker Inactivatum is recommended to be applied no later than by the start of the second trimester of each further pregnancy.

#### **4.3 Contraindications**

Do not use in unhealthy animals.

#### **4.4 Special warnings**

None.

#### **4.5 Special precautions for use**

Special precautions for use in animals

None.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Transient subcutaneous swelling up to 5 cm in diameter, which subsides within 14 days, may occur at the injection site in very rare cases. In very rare cases allergic reactions may occur as with other vaccines, therefore vaccinates should be observed for approximately 30 minutes following immunisation. In those cases, antiallergics should be administered.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Can be used during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Immunosuppressive substances, i.e. corticosteroids or Bovine Virus Diarrhoea modified live vaccines, should be avoided in a period of 7 days prior to and after vaccination as this may impair the development of the immunity.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

##### ***Posology***

The dose of vaccine is 2 ml for cattle over 3 months of age, for subcutaneous injection.

The vaccination scheme consists of basic immunisation and booster vaccinations.

Basic immunisation:

Two injections of 1 dose (2 ml) each 3-5 weeks apart.

Booster vaccinations of cattle having been administered the primary vaccination scheme using Rispoval IBR-Marker Inactivatum:

1 dose (2 ml) 6 months apart.

Booster Vaccinations of cattle having been administered the primary vaccination scheme using Rispoval IBR-Marker Vivum (in member states where this product is authorized):

Cattle having been administered the primary vaccination scheme using Rispoval IBR-Marker Vivum (according to the product information for this product) may be given booster vaccinations with Rispoval IBR-Marker Inactivatum. These animals should be given a single dose booster vaccination with Rispoval IBR-Marker Inactivatum 6 months after their initial vaccination course with Rispoval IBR-Marker Vivum. Thereafter, single dose booster vaccinations with Rispoval IBR-Marker Inactivatum should be administered every 12 months.

If calves under the age of 3 months should be vaccinated the development of immunity may be impaired by maternal antibodies. These calves should be revaccinated when they are over 3 months of age.

It is recommended to vaccinate all cattle of a herd.

To prevent abortions associated with BoHV-1 female cattle require a primary course of two subcutaneous doses of vaccine 3-5 weeks apart or alternatively a primary course of a single intramuscular dose of Rispoval IBR-Marker Vivum followed 6 months later by a single dose booster using Rispoval IBR-Marker Inactivatum. In order to cover the main abortion risk period, it is recommended that the second dose of the primary course of two subcutaneous doses or the single dose booster using Rispoval IBR-Marker Inactivatum is administered no later than by the start of the second trimester of each pregnancy.

### ***Method of administration***

Shake the vaccine well before use. The liquid suspension is injected aseptically via the subcutaneous route.

### Vaccination schemes summary

#### **From 2 weeks to 3 months of age**

<b>Rispoval IBR-Marker vaccine used</b>		<b>Revaccination intervals</b>	
<b>Primary vaccination</b>			
<b>First dose, from 2 weeks of age (route of administration)</b>	<b>Second dose, at 3 months of age (route of administration)</b>	<b>Interval to next booster vaccination (vaccine and route of administration)</b>	<b>All subsequent booster vaccinations (vaccine and route of administration)</b>
<b>Vivum (intranasal)</b>	<b>Vivum (intramuscular)</b>	<b>6 months (Vivum, intramuscular)</b>	<b>6 months (Vivum, intramuscular)</b>
<b>Vivum (intranasal)</b>	<b>Vivum (intramuscular)</b>	<b>6 months (Inactivatum, subcutaneous)</b>	<b>12 months (Inactivatum, subcutaneous)</b>

#### **From 3 months of age**

<b>Rispoval IBR-Marker vaccine used</b>	<b>Revaccination intervals</b>
---	--------------------------------

<b>Primary vaccination (number of doses and route of administration)</b>	<b>Interval to first booster vaccination (vaccine and route of administration)</b>	<b>All subsequent booster vaccinations (vaccine and route of administration)</b>
Vivum (one dose, intramuscular)	6 months (Vivum, intramuscular)	6 months (Vivum, intramuscular)
Vivum (one dose, intramuscular)	6 months (Inactivatum, subcutaneous)	12 months (Inactivatum, subcutaneous)
Inactivatum (two doses, subcutaneous, with 3-5 week interval)	6 months (Inactivatum, subcutaneous)	6 months (Inactivatum, subcutaneous)

For female cattle for protection against abortion:

<b>Risposal IBR-Marker vaccine used</b>	<b>Revaccination</b>
<b>Vaccination schedule (number of doses and route of administration) recommended to be applied no later than by the start of second trimester of pregnancy</b>	
Vivum (two doses, intramuscular, with 3-5 weeks interval)	Inactivatum (one dose, subcutaneous) recommended to be applied no later than by the start of the second trimester of each pregnancy
Vivum (one dose, intramuscular) followed by Inactivatum (one dose, subcutaneous), with 6 months interval	
Inactivatum (two doses, subcutaneous, with 3-5 week interval)	

For vaccination in known high BoHV-1 infection pressure:

<b>Risposal IBR-Marker vaccine used</b>	<b>Revaccination intervals</b>
---	--------------------------------

Primary vaccination (number of doses and route of administration)	Interval to first booster vaccination (vaccine and route of administration)	All subsequent booster vaccinations (vaccine and route of administration)
Vivum (one dose, intranasal), followed by Vivum (one dose, intramuscular) with 3-5 weeks interval	6 months (Vivum, intramuscular, OR Inactivatum, subcutaneous)	6 months (Vivum, intramuscular) OR 12 months (Inactivatum, subcutaneous)

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Reactions after administration of a double dose of vaccine are not different from those after the single dose.

#### 4.11 Withdrawal period(s)

Zero days.

### 5. IMMUNOLOGICAL PROPERTIES

Inactivated viral vaccine.  
ATCvet code: QI02AA03

The vaccine induces immunity in cattle against clinical respiratory symptoms caused by the Infectious Bovine Rhinotracheitis (IBR) virus. Following infection the intensity and duration of clinical symptoms as well as the titre and duration of virus shedding are significantly reduced. As with other vaccines, vaccination may not completely prevent but does reduce risk of infection. The product induces in vaccinated cattle antibodies, which are detected in the serum neutralisation test and in conventional ELISA tests. With specific test kits these antibodies can be differentiated - due to the lack of antibodies against gE - from those of field virus infected animals or animals vaccinated with conventional vaccines.

### 6. PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Phenolsulfonphthalein  
HEPES-Na  
Sodium thiosulfate  
Thiomersal  
Minimum Essential Medium

#### 6.2 Incompatibilities

Do not mix with any other veterinary medicinal product.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 36 months  
Shelf-life after first opening the immediate packaging: 8 hours

### **6.4 Special precautions for storage**

Store in a refrigerator (+2°C to +8°C). Protect from frost, heat or light.

### **6.5 Nature and composition of immediate packaging**

Multidose containers:

10 doses: 1 glass vial with 20 ml (10 doses) inactivated vaccine, closed with bromobutyl rubber stoppers and sealed with an aluminium ring with a flip-off cap, packed as 1 vial in a folding carton.

50 doses: 1 glass vial with 100 ml (50 doses) inactivated vaccine, closed with bromobutyl rubber stoppers and sealed with an aluminium ring with a flip-off cap, packed as 1 vial in a folding carton.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

## **8. MARKETING AUTHORISATION NUMBER**

Vm 42058/4127

## **9. DATE OF FIRST AUTHORISATION**

05 February 1999

**10. DATE OF REVISION OF THE TEXT**

14 November 2019

Approved 14 November 2019

A handwritten signature in black ink, consisting of a stylized, cursive 'H' followed by the word 'Hunter.' with a period.